Results 171 to 180 of about 16,883 (239)

Rapid development of drug resistance during initial dolutegravir-based antiretroviral therapy of an infant with HIV. [PDF]

South Afr J HIV Med
O'Connell NL, von Mollendorff TL, van Zyl G, Korsman S, Nuttall J.   +4 more
europepmc   +1 more source

Maturation inhibitors: a lost cause? [PDF]

EClinicalMedicine
Pozniak A.
europepmc   +1 more source

Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study. [PDF]

Clin Infect Dis
Loosli T, Bolton Moore C, Buzaalirwa L, Byakwaga H, Çelikağ İ, Chimbetete C, Ebasone PV, Giandhari J, Han N, Huwa J, Kasozi C, Mafoua A, Messou E, Minga A, Muula G, Muyindike W, Ndala ACM, Sauermann M, Semeere A, Singh L, Kouyos RD, Lessells R, Egger M.   +22 more
europepmc   +1 more source

Viral suppression in adults on efavirenz- or dolutegravir-based antiretroviral therapy in Mopani District, South Africa. [PDF]

South Afr J HIV Med
Njuguna C, Maluleke C, Davies N, Hans L, Mutasa B, Rees K.   +5 more
europepmc   +1 more source

Dual Inhibitory Potential of Conessine Against HIV and SARS-CoV-2: Structure-Guided Molecular Docking Analysis of Critical Viral Targets. [PDF]

Viruses
Abdulkareem AH, Alani MT, Awad SA, Al-Meani SAL, Ahmed MM, Abdulkareem EH, Khaleel ZM.   +6 more
europepmc   +1 more source

HIV Treatment Paradigm Shifts over the Past 40 Years. [PDF]

Jugan Geongang Gwa Jilbyeong
Heo JY.
europepmc   +1 more source

Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy

Nivriti Hurbans, Panjasaram Naidoo
openalex   +1 more source